Ayla Annac, CEO and Co-Founder, InvivoSciences shines light on the next generation of precision medicine and explains how IVS is personalizing the drug development process with patient-derived and gene-edited human samples. The company's Novel Heart Tissue on a chip platform NuHeart™ enables rapid identification of the safety and efficacy profile of a given treatment for a specific patient group. IVS is saving time and money in developing new therapies while increasing the success rate of approval for cardio safe therapies.
#COVID19 #ChronicHeartFailure
InvivoSciences.com
Download the transcript here
Empowered Patient Podcast